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For the ﬁrst time new treatments in melanoma have
produced signiﬁcant responses in advanced diseases,
but 30–90% of melanoma patients do not respond or
eventually relapse after the initial response to the
current treatments. The resistance of these melanomas
is likely due to tumor heterogeneity, which may be
explained by models such as the stochastic, hierarch-
ical, and phenotype-switching models. This review will
discuss the recent advancements in targeting BCL-2
family members for cancer treatments, and how this
approach can be applied as an alternative option to
combat melanoma, and overcome melanoma relapse
or resistance in current treatment regimens.
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THE NEED FOR DEVELOPING ALTERNATIVE MELANOMA
TREATMENT OPTIONS
Malignant melanoma is a devastating disease with historically
poor prognosis. For the ﬁrst time, several drugs provide a
signiﬁcant improvement in the overall survival of these
patients (Finn et al., 2012; Menaa, 2013; Lo and Fisher,
2014; Tronnier and Mitteldorf, 2014). These drugs fall into
two categories: they either block the mitogen-activated
protein kinase (MAPK) signaling pathway in BRAFV600E-
mutated melanoma, or they alter the patient’s own immune
system to attack melanoma. Pathway-targeting drugs include
BRAF inhibitors that speciﬁcally target the BRAFV600E muta-
tion (vemurafenib and dabrafenib) or MEK inhibitors (trame-
tinib and cobimetinib), either alone or in combination
(Flaherty et al., 2012). Recent clinical trials with the
combinations of both BRAF and MEK inhibitors showed
improvements in progression-free survival compared with a
single inhibitor in BRAFV600E melanoma patients but also with
increased side effects in some cases (Larkin et al., 2014;
Long et al., 2014a,b). Although these treatments lead to a
quick initial response, for instance ~50% of patients
respond to vemurafenib, responses are not durable
(Chapman et al., 2011). Most patients eventually relapse,
and the intrinsic or acquired resistance mechanisms include
reactivation of MAPK signaling through alternative pathways
or activation of other oncogenic pathways such as PI3K/AKT
(Fedorenko et al., 2011; Chapman, 2013). In addition,
patients without the BRAFV600E mutation do not beneﬁt from
these treatments.
For immunotherapy, the humanized monoclonal antibo-
dies ipilimumab and pembrolizumab block the negative
regulators of immune responses, thereby stimulating T-cell
response against melanoma (Gyorki et al., 2013; Drake et al.,
2014). Ipilimumab targets CTLA-4 (Hodi et al., 2010) and
pembrolizumab targets PD-1 (Robert et al., 2014). Efﬁcacy
with ipilimumab is longer than that with BRAF/MAPK/ERK
kinase inhibitors, but the response rate is poor at only 10–15%
(Hodi et al., 2010). A distinct genetic landscape of neoanti-
gens is reported to be present in melanomas with a strong
response to ipilimumab (Snyder et al., 2014). Moreover, both
antibodies lead to signiﬁcant immune-mediated side effects
(Finn et al., 2012), and relapse rate is not yet known for
pembrolizumab. Therefore, many patients do not respond to
current therapies, and there is still a pressing need to develop
alternative treatment options for metastatic melanoma,
especially for those with wild-type BRAF.
Human tumors are composed of heterogeneous cell popu-
lations. Tumor heterogeneity is implicated in tumor cells’
resistance to treatment and may be explained by several
models. The stochastic (clonal evolution) model states that
every cell within a tumor has similar tumorigenic and self-
renewing potential. These cells evolve and lead to hetero-
geneity, through clonal expansion with acquired genetic and
epigenetic changes over time (Nowell, 1976; Shackleton
et al., 2009; Greaves and Maley, 2012). This process is
inﬂuenced by extrinsic factors including therapies. In contrast,
the hierarchical model states that only a subpopulation of
tumor cells, cancer stem cells (CSCs), possess self-renewal
capacity and contribute to intra-tumoral heterogeneity by
giving rise to non-CSCs within the same tumor (Reya et al.,
2001; Clarke et al., 2006; Frank et al., 2010; Nguyen et al.,
2012). This model suggests that eliminating CSCs will help in
eradicating tumors. Cancer cell plasticity also contributes to
tumor heterogeneity by mechanisms such as phenotype-
switching. Cells may switch among proliferative, invasive,
and stem cell-like states in response to microenvironments
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(Hoek et al., 2008; Hoek and Goding, 2010; Cheli et al.,
2011,2012). Moreover, a dynamic process mediated by a
temporarily distinct subpopulation may also contribute to
melanoma heterogeneity (Roesch et al., 2010). These models/
mechanisms are not mutually exclusive. The CSC populations
themselves are heterogeneous and dynamic and may evolve
through clonal evolution or display phenotype switching
(Lee et al., 2014; Nguyen et al., 2015). In melanoma, the high
mutation load also likely contributes to heterogeneity.
Interestingly, wild-type BRAF/NRAS melanomas seem to have
a higher mutation load compared with mutant BRAF/NRAS
tumors (Mar et al., 2013).
To prevent relapse, it is proposed that effective
therapy needs to eradicate all subpopulations of tumor cells,
killing the mass of cancer cells (de-bulking), as well as any
resistant subpopulations such as CSCs (Han et al., 2013).
One known cancer resistance mechanism is the dysregulation
of BCL-2 family members, and recent studies indicate
that this also contributes to the survival of CSCs. This
review provides an overview of developing new melanoma
treatments by targeting BCL-2 dysregulation with the
purpose of de-bulking melanomas and eliminating drug-
resistant subpopulations of CSCs in melanoma. We include
the rationale, methods used and the current promising
approaches.
THE REGULATION OF APOPTOSIS BY THE BCL-2 FAMILY
The BCL-2 family of proteins has a crucial role in regulating
intrinsic or mitochondrial apoptosis (Czabotar et al., 2014).
The members are divided into three groups on the basis of
their functions and structures: (i) anti-apoptotic proteins (also
called inhibitors), which include Bcl-2, Bcl-XL, Bcl-w, Mcl-1,
A1, and BCL-B; (ii) multi-BH domain pro-apoptotic proteins
(also called effectors), which include BAX and BAK; (iii) and
BH3-only pro-apoptotic proteins (also called activators or
enhancers), which include NOXA, BIM, BID, BAD, BMF, BIK,
and others (Figure 1a). Upon activation, the effectors (BAX/
BAK) oligomerize, triggering cytochome C release from the
mitochondria and apoptosome activation, and ﬁnally result in
caspase-9-dependent apoptosis (Czabotar et al., 2014). Anti-
apoptotic proteins bind to BAX/BAK, preventing their activa-
tion. The balance of the interactions between different
BCL-2 family members determines whether cells will initiate
apoptosis (Chipuk et al., 2010; Mohana-Kumaran et al.,
2014). Some BH3-only members only bind to one group of
inhibitors––for example, NOXA only binds to MCL-1/A1.
Others can bind to multiple inhibitors, such as BIM, PUMA,
and tBID.
BAX/BAK oligomerization is necessary for activation of
apoptosis, and the activation has been proposed to be direct
or indirect (Czabotar et al., 2014). In the direct activation
model, the BH3-only proteins directly bind to effectors (BAX/
BAK) leading to activation. In the indirect model, binding of
BH3-only proteins to the inhibitors releases the effectors BAX/
BAK, allowing for activation. In the indirect model, apoptosis
only occurs when all the anti-apoptotic members are
neutralized. These two models are not mutually exclusive;
one may be more dominant than the other, depending on the
circumstances. Nevertheless, in both models, the binding of
BH3-only proteins to anti-apoptotic members can activate
effectors and induce apoptosis (Czabotar et al., 2014). Thus,
mimicking the pro-apoptotic BH3-only proteins by small
molecules is a logical approach to develop cancer drugs
(Ni Chonghaile and Letai, 2008; Billard, 2013; Mohana-
Kumaran et al., 2014).
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Figure 1. Targeting the BCL-2 family as a treatment option for melanoma.
(a) A simpliﬁed illustration for the rationale to target BCL-2 family members
in melanoma. Green box represents the pro-apoptotic proteins, and red box
represents the anti-apoptotic proteins. Multiple BCL-2 proteins are
downstream of the RAS/BRAF/mitogen-activated protein kinase (MAPK) and
PI3K/AKT signaling pathways, the commonly activated pathways in
melanoma. The activation of these pathways leads to the dysregulated
expression of multiple BCL-2 proteins and likely contributes to resistance to
cell death in melanoma. For instance, the activated RAS/BRAF/MAPK signal
upregulates MCL-1 and blocks BIM and BAD (see text for details). Thus,
targeting the BCL-2 family may provide an alternative way to combat
melanoma regardless of its BRAF status and to overcome melanoma relapse
from current treatments. (b) Combination therapy debulk and kills the
melanoma stem cells (MSCs). The various blue cells represent heterogeneous
non-MSCs populations, and the yellow cells represent the MSC populations.
Standard therapy may be successful in de-bulking melanoma cells initially.
However, it fails to kill MSCs, resulting in tumor relapse due to the self-
renewal capacity of MSCs. The combination therapy targeting multiple BCL-2
anti-apoptotic members debulks and kills the MSCs, preventing future relapse
of melanoma.
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THE RATIONALE TO TARGET BCL-2 FAMILY MEMBERS IN
MELANOMA
Dysregulation of BCL-2 family proteins occurs frequently and
has a major role in conferring resistance to cell death in many
cancers, including melanoma (Norris, 1995; Plati et al.,
2011). Importantly, many BCL-2 proteins are downstream of
the commonly activated signaling pathways RAS/BRAF/MAPK
and PI3K/AKT (Figure 1a; Kwong and Davies, 2013;
Haass and Schumacher, 2014). For instance, oncogenic
BRAFV600E suppresses apoptosis by upregulating anti-apoptotic
MCL-1 (McKee et al., 2013; Haass and Schumacher, 2014).
Also, through phosphorylation, constitutively activated
RAS/BRAF/MAPK signals downregulate or inactivate pro-
apoptotic BAD (Eisenmann et al., 2003) or BIM (Goldstein
et al., 2009). Third, activated PI3K/AKT signals inhibit cell
death by inactivating BAD’s ability to bind BCL-2 or BCL-XL
(Datta et al., 1999; Steelman et al., 2011) or downregulating
transcription of pro-apoptotic members BIM and PUMA
through sequestering the transcription factors FOXOs away
from their promoters (Zhang et al., 2011). Activated AKT also
prevents induction of pro-apoptotic BIM-EL and BMF upon
BRAF inhibition, contributing to melanoma resistance to
BRAF inhibitors (Shao and Aplin, 2010; Figure 1a). Moreover,
gene ampliﬁcation results in upregulation of anti-apoptotic
BCL2A1 in some melanoma (Haq et al., 2013). Furthermore,
the melanocyte-speciﬁc transcription factor (microphthalmia-
associated transcription factor) is ampliﬁed in a subset of
melanoma, which can upregulate BCL-2 and contribute to
resistance to cell death (Hartman and Czyz, 2015).
The effects of BRAF inhibitors in melanoma are dependent
on the induction of BH3-only protein BIM and BMF
(Shao and Aplin, 2010); BIM repression by epigenetic chromatin
remodeling (Shao and Aplin, 2012) contributes to mela-
noma resistance to BRAF inhibition. Considering that some
BCL-2 family members are regulated by MAPK or PI3K/AKT
signaling and that activation of these pathways contributes to
relapses from treatment of BRAF inhibitor, targeting down-
stream apoptotic proteins may be alternative options to
overcome relapse. Indeed, the BAD mimetic, ABT-737, has
been shown to overcome AKT-mediated resistance to BRAF
inhibition (Perna et al., 2015).
Taken together, multiple mechanisms lead to dysregulation
of the BCL-2 family, and this likely contributes to melanoma
development of resistance to current treatments (Figure 1a).
Thus, targeting the BCL-2 family is an alternative way to
combat melanoma, independent of BRAF mutation status, and
overcome melanoma relapse from current treatments.
DE-BULKING CANCER CELLS BY TARGETING BCL-2
FAMILY MEMBERS
Single agents targeting BCL-2 or MCL-1
Early attempts at targeting BCL-2 family members included
antisense, single-chain antibodies, ribozymes, BH3 peptides,
and hydrocarbon stapling. However, most failed, possibly
because of poor delivery systems and the short-term stability
of the compounds (see review Thomas et al., 2013). Current
more successful approaches focus on stable small molecule
inhibitors (SMI), called “BH3 mimetics”, which mimic the
pro-apoptotic BH3-only proteins to induce apoptosis in
cancer cells (Table 1).
Currently, ABT-263 (navitoclax) and ABT-199 are in
clinical trials, with encouraging preliminary results
(Wilson et al., 2010; Gandhi et al., 2011; Roberts et al.,
2012). ABT-263, an oral version of ABT-737, is a mimetic of
BH3-only BAD that inhibits BCL-2, BCL-XL, and BCL-W but
not MCL-1 (Oltersdorf et al., 2005; van Delft et al., 2006;
Tse et al., 2008). ABT-199 was modiﬁed from ABT-263, with
a sub-nano-molar afﬁnity for BCL-2 but not BCL-XL (Davids
and Letai, 2013). Unfortunately, single agent treatment of
melanoma with ABT-737/ABT-263 is not effective, with
MCL-1 as the main contributor of resistance (Chen et al.,
2007; Miller et al., 2009; Lucas et al., 2012).
MCL-1 overexpression is linked to the pathogenesis of
multiple cancers, including melanoma (Boisvert-Adamo et al.,
2009; Khodadoust et al., 2009; Thomas et al., 2010;
McKee et al., 2013). Many groups are developing SMIs that
target MCL-1 with the aim of overcoming cancer resistance to
ABT-737/263. Promising compounds include Maritoclax,
WP1130, UMI-77, Clitocine, and Compound 11, with some
efﬁcacy in animal studies (Quinn et al., 2011; Wei et al.,
2012; Belmar and Fesik, 2014; Sun et al., 2014). However,
clinical trials are still needed (Table 1).
Combination therapy
As mentioned above, targeting a single BCL-2 family member
is not sufﬁcient to kill melanoma. In addition, therapeutics
with single molecular targets often fails because of the
heterogeneity and dynamic nature of cancer cells. Thus,
utilizing combination therapies is an emerging strategy to treat
cancer. Combination therapy increases the number of cells
responding to treatment, decreases the possibility of drug
resistance, kills heterogeneous populations of cells within the
tumor, and may also lower side effects.
Several combination strategies target BCL-2 family mem-
bers, with promising pre-clinical evidence (Table 1). As
mentioned earlier, MCL-1 is the main mediator of melanoma
resistance to BCL-2 inhibitors such as ABT-737, and NOXA is
a pro-apoptotic BH3-only protein that inhibits MCL-1. There-
fore, inhibiting BCL-2, combined with either inhibition of
MCL-1 or activation of NOXA, is effective at killing melanoma
(Miller et al., 2009; Reuland et al., 2011; Lucas et al., 2012;
Reuland et al., 2012; Mukherjee et al., 2015). Another
strategy is sensitizing melanoma with BCL-2 SMIs, coupling
with molecular-targeted agents such as BRAF inhibitors
(Wroblewski et al., 2013). The last strategy combines BCL-2
SMIs with immune therapies, again using BH3 mimetics such
as ABT-737, to sensitize tumor cells to immunotherapies
(Begley et al., 2009; Karlsson et al., 2013). All these appro-
aches provide treatment opportunities that may limit escape
mechanisms in different patients and enhance the possibilities
for personalized cancer medicine approach to treatment.
Although the above strategies are promising, none explored
the effectiveness of speciﬁcally eradicating resistant subpo-
pulations, which is an important contributor for melanoma
resistance.
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CSCs IN MELANOMA
CSCs are deﬁned as a subpopulation of cancer cells that
possess two essential stem cell functions: self-renewal and
differentiation (Clarke et al., 2006). CSCs enhance cancer
initiation, progression, metastasis, and chemoresistance
(Clarke et al., 2006; Nguyen et al., 2012; Pattabiraman and
Weinberg, 2014). CSCs also contribute to intra-tumoral
heterogeneity, with their ability to give rise to non-CSCs
within the same tumor (Frank et al., 2010; Pattabiraman and
Weinberg, 2014). To prevent relapse, targeting CSCs should
be an important part of treatment strategies.
The gold standard method to conﬁrm the existence of CSCs
is to detect their capacity to self-renew and differentiate, using
in vivo serial xenotransplantation assays (Clarke et al., 2006).
Recently, several lineage tracing studies with genetically
engineered mouse models provided further evidence for the
existence of CSCs (Pattabiraman and Weinberg, 2014). To
date, CSCs have been identiﬁed in many cancers (Tabarestani
and Ghafouri-Fard, 2012; Pattabiraman and Weinberg, 2014).
Quintana and colleagues reported a high frequency of
tumor-initiating cells (TICs) in human melanoma using highly
permissive conditions, raising questions on the existence of
CSCs in human melanoma (Quintana et al., 2008). However,
TICs are not the same as CSCs with self-renewal and
differentiation capacity (Shakhova and Sommer, 2013), and
the high frequency of TICs does not disprove the presence
of CSCs (see reviews (Lang et al., 2013; Shakhova and
Sommer, 2013; Lee et al., 2014; Nguyen et al., 2015)). Rather,
Quintana’s papers simply suggest that TICs are inﬂuenced by
many experimental factors. Indeed, when using the gold
standard in vivo assays, numerous groups have detected
subpopulations of melanoma cells that fulﬁll the criteria
for CSCs (Lang et al., 2013; Shakhova and Sommer, 2013;
Lee et al., 2014; Nguyen et al., 2015), and these cells are
associated with tumor progression and chemoresistance.
Several melanoma stem cell (MSC) markers have been
suggested in peer-reviewed literatures, and these include cell
surface markers ABCB5 (Schatton et al., 2008) and CD271
(Boiko et al., 2010; Civenni et al., 2011; Redmer et al., 2014)
and activity of aldehyde dehydrogenase (a detoxifying
enzyme; Luo et al., 2012). ABCB5 belongs to the ATP-
binding cassette transporter superfamily, implicated in multi-
drug resistance. CD271 is a nerve growth factor receptor and
is also a marker of mesenchymal stem cells (Watson et al.,
2013) and hypopharyngeal CSCs (Imai et al., 2013). However,
recent evidence suggests that not all CD271+ cells are the
same, and only the slow growing CD271+ population
displays a high tumorigenic potential and stemness (Cheli
et al., 2014). In addition, knockdown of CD271 alone
decreases, but does not prevent, the accumulation of the
Table 1. Examples of SMIs targeted BCL-2 family members in clinical trials or pre-clinical studies
SMI Target(s)
Clinical trials or pre-clinical studies
Cancer type Combination drug Clinical trialsa
Gossypol BCL-2
BCL-XL
MCL-1
BCL-W
BCL-B
Adrenocortical carcinoma
Lymphoma
Advanced SCLC, solid tumors
Advanced prostate cancer
NA
Paclitaxel, carboplatin
Cisplatin, etoposide
Bicalutamide
II
I
I
II
Obatoclax BCL-2
MCL-1
BCL-XL
BCL-W
BCL-B
BFL-1
Advanced SCLC
AML
CLL
Hodgkins lymphoma
MCL, Lymphoma
NSCLC
SCLC
Carboplatin, etoposide
NA
NA
NA
Bortezomib
Docetaxel
Topotecan hydrochloride
I/II
II
I/II
II
I/II
I/II
I/II
ABT-263 (ABT-737) BCL-2
BCL-XL
BCL-W
CLL, SCLC, Leukemia
Lymphoma, CLL, solid tumors
CLL
Solid tumors
Lymphoma; CLL
NA
Ketoconaxole
Fludarabine, Cyclophosphomide, Rituximab
Doxetaxel, Gemcitabine, Etoposide, Cisplatin, Paclitaxel
Rifampin
II,I,II
I
I
I
I; II
ABT-199 BCL-2 SLL, NHL, CLL, AML
B-cell lymphoma
NA
Rituximab
I; II
IB
Maritoclax MCL-1 Melanoma
AML
Single and with ABT-737; in vitro and in vivo
Single; in vitro
NA
Clitocine MCL-1 Hepatocellular carcinoma Single; in vitro and in vivo NA
UMI-77 MCL-1 Pancreatic cancer Single; in vitro and in vivo NA
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; NA, not available; NHL, non-Hodgkin’s
lymphoma; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; SLL, small lymphocytic leukemia; SMI, small molecule inhibitor.
None of the MCL-1 inhibitors listed are in clinical trials yet; thus, we provided the information based on the pre-clinical studies for these instead. More details
can be found in the reviews by Belmar and Fesik, 2014; and Thomas et al., 2013.
aThe information for clinical trials is adapted from www.clinicaltrials.gov
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stress-induced drug-resistant cell population (Menon et al.,
2015). These recent data suggest that CD271 may be an
imperfect MSC marker.
In sum, subpopulations of melanoma cells possess char-
acteristics of CSCs (tumorigenesis with self-renewal and
differentiation capacities), with enhanced ability for mela-
noma initiation, maintenance, and resistance to treatments.
Although various markers can enrich MSCs, the most critical
functional trait of these subpopulations is their self-renewal
capacity for long-term growth of melanoma. Therefore, self-
renewability of these subpopulations should be targeted to
prevent relapse after treatment.
ERADICATING CSCs BY TARGETING BCL-2 FAMILY
MEMBERS
Ideally, cancer treatments should eliminate both non-CSCs
(the bulk of the tumors) and CSCs (Frank et al., 2010;
Rameshwar, 2014). Utilizing combination therapy is likely the
best strategy for targeting all subpopulations in heterogeneous
tumors, and promising new drugs should test the efﬁcacy of
killing CSCs.
Potential strategies that focus on CSCs include differentiat-
ing CSCs into mature cells with no self-renewal capacity,
eliminating CSCs by targeting essential pathways, or disrupt-
ing their niche. A successful example of differentiation therapy is
the use of all-trans retinoic acid on acute promyelocytic
leukemia patients to differentiate the cancer cells into mature
granulocytes (Pattabiraman and Weinberg, 2014). Another
approach to kill CSCs is through targeting their dependent
signaling pathways, such as NOTCH, ATP-binding cassettes,
NF-κB, transforming growth factor-β, WNT, and JAK-signal
transducer and activator of transcription (Chen et al., 2013;
Pattabiraman and Weinberg, 2014). In addition, tumor
microenvironment may serve as CSC’s niche and can also
be a drug target to eliminate CSCs. For example, angiogenesis
is crucial in maintaining tumor niches, and the melanoma
niche encompasses a network consisting of not only endo-
thelial-lined blood vessels but also “vasculogenic mimicry”
channels formed by melanoma cells (Lai et al., 2012). Drugs
targeting angiogenesis (such as vascular endothelial growth
factor inhibitors) can disrupt tumor niche and indirectly
eradicate CSCs (Schatton et al., 2008; Frank et al., 2011;
Lee et al., 2014; Pattabiraman and Weinberg, 2014).
Numerous recent studies show that CSCs are
especially vulnerable to SMIs targeting the BCL-2 family.
Lagadinou et al. (2013) showed that BCL-2 was overexpressed
in quiescent leukemia stem cells with low levels of reactive
oxygen species, and BCL-2 inhibitor ABT-263 selectively
eradicated the leukemia stem cells (Lagadinou et al., 2013). In
bone-marrow-resident human leukemia stem cells, splice-
isoform switching favored expression of multiple pro-survival
BCL-2 members, and a pan-BCL-2 inhibitor sensitized them to
tyrosine kinase inhibitors (Goff et al., 2013). Other CSCs, such
as breast and colon CSCs, displayed upregulated BCL-2
(Fulda, 2013). BCL-XL overexpression contributed to survival
of colon CSCs (Colak et al., 2014) and lung CSCs (Zeuner
et al., 2014). When treated with ABT-737 but not ABT-199,
these cells died (Zeuner et al., 2014) or were sensitized to
chemotherapies (Colak et al., 2014). Furthermore, suppressing
MCL-1 may overcome the tumor-plasticity-induced drug
resistance in multiple myeloma cells (Dalva-Aydemir et al.,
2014). These ﬁndings highlight that inhibition of pro-survival
BCL-2 family proteins is a promising approach to target
chemotherapy-resistant CSCs and plasticity of tumors.
To our knowledge, few studies explored the BCL-2 family
members as targets for eradicating heterogeneous melanomas
or MSCs. Recently, we identiﬁed the combination of a BCL-2
Inhibitor with the retinoid derivative fenretinide as a promis-
ing treatment, for both wild-type and mutant BRAF cells and
for non-MSCs and MSCs (Mukherjee et al., 2015; Figure 1b).
The combination synergistically inhibited melanoma growth
in vitro and in vivo, disrupted melanoma spheres, decreased
the percentage of ALDHhigh cells, and inhibited the self-renewal
capacity of MSCs. These effects were observed in melanoma
cells with mutations of either BRAF or NRAS. Interestingly,
single drug treatments increased characteristics of MSCs for
some melanoma samples, and only the combination treatment
signiﬁcantly reduced the self-renewal capacity of MSCs in all
the samples tested. Proliferation stopped post treatment, with no
re-growth of tumor cells. The mechanism of action for the
combination involves antagonizing multiple anti-apoptotic
BCL-2 members at once (Mukherjee et al., 2015; Figure 1b).
These results support the idea that combination treatments are
more potent to eliminate MSCs or other resistant subpopula-
tion and targeting multiple pro-survival BCL-2 family mem-
bers is a promising approach for melanoma (Figure 1b).
SUMMARY
By killing heterogeneous tumors and eliminating drug-resistant
subpopulations, SMIs, targeting multiple BCL-2 family members,
provide an option for melanoma, especially the wild-type BRAF
melanomas. This approach thus offers an alternative way to
combat melanoma and may help achieve longer lasting
treatment effects.
CONFLICT OF INTEREST
The authors state no conﬂict of interest.
ACKNOWLEDGMENTS
This work was supported in part by a Southwestern Skin Cancer SPORE Pilot
project and NIH/NIAMS R03AR064555 to YGS and by a Veterans Adminis-
tration merit grant from the Department of Veterans Affairs (Veterans Health
Administration, Ofﬁce of Research and Development, Biomedical Laboratory
Research and Development) to DAN. We apologize to all the colleagues
whose important work is not cited because of the space constrain. We thank
Karoline Lambert for her help on editing the manuscript.
REFERENCES
Begley J, Vo DD, Morris LF et al. (2009) Immunosensitization with a Bcl-2 small
molecule inhibitor. Cancer Immunol Immunother 58:699–708
Belmar J, Fesik SW (2014) Small molecule Mcl-1 inhibitors for the treatment
of cancer. Pharmacol Ther 145:76–84
Billard C (2013) BH3 mimetics: status of the ﬁeld and new developments. Mol
Cancer Ther 12:1691–700
Boiko AD, Razorenova OV, van de Rijn M et al. (2010) Human melanoma-
initiating cells express neural crest nerve growth factor receptor CD271.
Nature 466:133–7
N Mukherjee et al.
Targeting BCL-2 Family Members to De-Bulk and Kill CSCs
www.jidonline.org 2159
Boisvert-Adamo K, Longmate W, Abel EV et al. (2009) Mcl-1 is required for
melanoma cell resistance to anoikis. Mol Cancer Res 7:549–56
Chapman PB (2013) Mechanisms of resistance to RAF inhibition in melanomas
harboring a BRAF mutation. Am Soc Clin Oncol Educ Book 33:e80–2
Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:
2507–16
Cheli Y, Bonnazi VF, Jacquel A et al. (2014) CD271 is an imperfect marker for
melanoma initiating cells. Oncotarget 5:5272–83
Cheli Y, Giuliano S, Botton T et al. (2011) Mitf is the key molecular switch
between mouse or human melanoma initiating cells and their differen-
tiated progeny. Oncogene 30:2307–18
Cheli Y, Giuliano S, Fenouille N et al. (2012) Hypoxia and MITF control
metastatic behaviour in mouse and human melanoma cells.Oncogene 31:
2461–70
Chen K-F, Su J-C, Liu C-Y et al. (2012) A novel obatoclax derivative, SC-2001,
induces apoptosis in hepatocellular carcinoma cells through SHP-1-
dependent STAT3 inactivation. Cancer Lett 321:27–35
Chen K, Huang YH, Chen JL (2013) Understanding and targeting cancer stem cells:
therapeutic implications and challenges. Acta Pharmacol Sin 34:732–40
Chen S, Dai Y, Harada H et al. (2007) Mcl-1 down-regulation potentiates
ABT-737 lethality by cooperatively inducing Bak activation and Bax
translocation. Cancer Res 67:782–91
Chipuk JE, Moldoveanu T, Llambi F et al. (2010) The BCL-2 family reunion.
Mol Cell 37:299–310
Civenni G, Walter A, Kobert N et al. (2011) Human CD271-positive melanoma
stem cells associated with metastasis establish tumor heterogeneity and
long-term growth. Cancer Res 71:3098–109
Clarke MF, Dick JE, Dirks PB et al. (2006) Cancer stem cells–perspectives on
current status and future directions: AACR workshop on cancer stem cells.
Cancer Res 66:9339–44
Colak S, Zimberlin CD, Fessler E et al. (2014) Decreased mitochondrial priming
determines chemoresistance of colon cancer stem cells. Cell Death Differ
21:1170–7
Czabotar PE, Lessene G, Strasser A et al. (2014) Control of apoptosis by the
BCL-2 protein family: implications for physiology and therapy. Nat Rev
Mol Cell Biol 15:49–63
Dalva-Aydemir S, Bajpai R, Martinez M et al. (2014) Targeting the metabolic
plasticity of multiple myeloma with FDA approved ritonavir and
metformin. Clin Cancer Res 21:1161–71
Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts.
Genes Dev 13:2905–27
Davids MS, Letai A (2013) ABT-199: taking dead aim at BCL-2. Cancer Cell 23:
139–41
Drake CG, Lipson EJ, Brahmer JR (2014) Breathing new life into immunother-
apy: review of melanoma, lung and kidney cancer.Nat Rev Clin Oncol 11:
24–37
Eisenmann KM, VanBrocklin MW, Staffend NA et al. (2003) Mitogen-activated
protein kinase pathway-dependent tumor-speciﬁc survival signaling in
melanoma cells through inactivation of the proapoptotic protein bad.
Cancer Res 63:8330–7
Fedorenko IV, Paraiso KH, Smalley KS (2011) Acquired and intrinsic BRAF
inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharma-
col 82:201–9
Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the
past, present, and future. BMC Med 10:23
Flaherty KT, Robert C, Hersey P et al. (2012) Improved survival with MEK
inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–14
Frank NY, Schatton T, Frank MH (2010) The therapeutic promise of the cancer
stem cell concept. J Clin Invest 120:41–50
Frank NY, Schatton T, Kim S et al. (2011) VEGFR-1 expressed by malignant
melanoma-initiating cells is required for tumor growth. Cancer Res 71:
1474–85
Fulda S (2013) Regulation of apoptosis pathways in cancer stem cells. Cancer
Lett 338:168–73
Gandhi L, Camidge DR, de Oliveira MR et al. (2011) Phase I study of Navitoclax
(ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung
cancer and other solid tumors. J Clin Oncol 29:909–16
Goff DJ, Court Recart A, Sadarangani A et al. (2013) A Pan-BCL2 inhibitor
renders bone-marrow-resident human leukemia stem cells sensitive to
tyrosine kinase inhibition. Cell Stem Cell 12:316–28
Goldstein NB, Johannes WU, Gadeliya AV et al. (2009) Active N-Ras and B-Raf
inhibit anoikis by downregulating Bim expression in melanocytic cells.
J Investig Dermatol Symp Proc 129:432–7
Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306–13
Gyorki D, Callahan M, Wolchok JD et al. (2013) The delicate balance of
melanoma immunotherapy. Clin Translat Immunol 2:e5
Haass NK, Schumacher U (2014) Melanoma never says die. Exp Dermatol 23:
471–2
Han L, Shi S, Gong T et al. (2013) Cancer stem cells: therapeutic implications
and perspectives in cancer therapy. Acta Pharm Sin B 3:65–75
Haq R, Yokoyama S, Hawryluk EB et al. (2013) BCL2A1 is a lineage-speciﬁc
antiapoptotic melanoma oncogene that confers resistance to BRAF
inhibition. Proc Natl Acad Sci USA 110:4321–6
Hartman ML, Czyz M (2015) Pro-survival role of MITF in melanoma. J Investig
Dermatol Symp Proc 135:352–8
Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med 363:
711–23
Hoek KS, Eichhoff OM, Schlegel NC et al. (2008) In vivo switching of human
melanoma cells between proliferative and invasive states. Cancer Res 68:
650–6
Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in
melanoma. Pigment Cell Melanoma Res 23:746–59
Imai T, Tamai K, Oizumi S et al. (2013) CD271 deﬁnes a stem cell-like
population in hypopharyngeal cancer. PLoS One 8:e62002
Karlsson H, Lindqvist AC, Fransson M et al. (2013) Combining CAR T cells and
the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malig-
nancy. Cancer Gene Ther 20:386–93
Khodadoust MS, Verhaegen M, Kappes F et al. (2009) Melanoma proliferation
and chemoresistance controlled by the DEK oncogene. Cancer Res 69:
6405–13
Kwong LN, Davies MA (2013) Navigating the therapeutic complexity of PI3K
pathway inhibition in melanoma. Clin Cancer Res 19:5310–9
Lagadinou ED, Sach A, Callahan K et al. (2013) BCL-2 inhibition targets
oxidative phosphorylation and selectively eradicates quiescent human
leukemia stem cells. Cell Stem Cell 12:329–41
Lai C, Schwartz BE, Hsu M (2012) CD133+ melanoma subpopulations
contribute to perivascular niche morphogenesis and tumorigenicity
through vasculogenic mimicry. Cancer Res 72:5111–8
Lang D, Mascarenhas JB, Shea CR (2013) Melanocytes, melanocyte stem cells,
and melanoma stem cells. Clin Dermatol 31:166–78
Larkin J, Ascierto PA, Dreno B et al. (2014) Combined vemurafenib and
cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–76
Lee N, Barthel SR, Schatton T (2014) Melanoma stem cells and metastasis:
mimicking hematopoietic cell trafﬁcking? Lab Invest 94:13–30
Lo JA, Fisher DE (2014) The melanoma revolution: from UV carcinogenesis to a
new era in therapeutics. Science 346:945–9
Long GV, Stroyakovskiy D, Gogas H et al. (2014a) Combined BRAF and MEK
inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:
1877–88
Long GV, Stroyakovsky DL, Gogas H et al. (2014b) COMBI-d: A randomized,
double-blinded, Phase III study comparing the combination of dabrafenib
and trametinib to dabrafenib and trametinib placebo as ﬁrst-line therapy in
patients (pts) with unresectable or metastatic BRAFV600E/Kmutation-
positive cutaneous melanoma. In: Journal Of Clinical Oncology (2014)
ASCO Annual Meeting, Suppl; abstr 9011.
Lucas KM, Mohana-Kumaran N, Lau D et al. (2012) Modulation of NOXA and
MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic
ABT-737. Clin Cancer Res 18:783–95
N Mukherjee et al.
Targeting BCL-2 Family Members to De-Bulk and Kill CSCs
2160 Journal of Investigative Dermatology (2015), Volume 135
Luo Y, Dallaglio K, Chen Y et al. (2012) ALDH1A isozymes are markers of
human melanoma stem cells and potential therapeutic targets. Stem Cells
30:2100–13
Mar VJ, Wong SQ, Li J et al. (2013) BRAF/NRAS wild-type melanomas have a
high mutation load correlating with histologic and molecular signatures of
UV damage. Clin Cancer Res 19:4589–98
McKee DS H, CP R et al. (2013) Oncogenic BRAF signalling increases Mcl-1
expression in cutaneous metastatic melanoma. Exp Dermatol 22:767–9
Menaa F (2013) Latest approved therapies for metastatic melanoma: what
comes next? J Skin Cancer 2013:735282
Menon DR, Das S, Krepler C et al. (2015) A stress-induced early innate response
causes multidrug tolerance in melanoma.Oncogene; e-pub ahead of print;
doi:10.1038/onc.2014.432
Miller LA, Goldstein NB, Johannes WU et al. (2009) BH3 mimetic ABT-737 and
a proteasome inhibitor synergistically kill melanomas through Noxa-
dependent apoptosis. J Investig Dermatol Symp Proc 129:964–71
Mohana-Kumaran N, Hill DS, Allen JD et al. (2014) Targeting the intrinsic
apoptosis pathway as a strategy for melanoma therapy. Pigment Cell
Melanoma Res 27:525–39
Mukherjee N, Reuland SN, Lu Y et al. (2015) Combining a BCL2 inhibitor with
the retinoid derivative fenretinide targets melanoma cells including
melanoma initiating cells. J Investig Dermatol Symp Proc 135:842–50
Nguyen LV, Vanner R, Dirks P et al. (2012) Cancer stem cells: an evolving
concept. Nat Rev Cancer 12:133–43
Nguyen N, Couts KL, Luo Y et al. (2015) Understanding melanoma stem cells.
Melanoma Manag
Ni Chonghaile T, Letai A (2008) Mimicking the BH3 domain to kill cancer cells.
Oncogene 27:S149–57
Norris DA (1995) Differential control of cell death in the skin. Arch Dermatol
131:945–8
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:
23–8
Oltersdorf T, Elmore SW, Shoemaker AR et al. (2005) An inhibitor of Bcl-2
family proteins induces regression of solid tumours. Nature 435:677–81
Pattabiraman DR, Weinberg RA (2014) Tackling the cancer stem cells–what
challenges do they pose? Nat Rev Drug Discov 13:497–512
Perna D, Karreth FA, Rust AG et al. (2015) BRAF inhibitor resistance mediated
by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc
Natl Acad Sci USA 112:E536–45
Plati J, Bucur O, Khosravi-Far R (2011) Apoptotic cell signaling in cancer
progression and therapy. Integr Biol 3:279–96
Quinn BA, Dash R, Azab B et al. (2011) Targeting Mcl-1 for the therapy
of cancer. Exp Opin Invest Drugs 20:1397–411
Quintana E, Shackleton M, Sabel MS et al. (2008) Efﬁcient tumour formation by
single human melanoma cells. Nature 456:593–8
Rameshwar P (2014) Future challenges to target cancer stem cells. Enliven:
Challenges Cancer Detect Ther 1:001
Redmer T, Welte Y, Behrens D et al. (2014) The nerve growth factor receptor
CD271 is crucial to maintain tumorigenicity and stem-like properties of
melanoma cells. PLoS One 9:e92596
Reuland SN, Goldstein NB, Partyka KA et al. (2011) The combination of BH3-
mimetic ABT-737 with the alkylating agent temozolomide induces strong
synergistic killing of melanoma cells independent of p53. PLoS One 6:
e24294
Reuland SN, Goldstein NB, Partyka KA et al. (2012) ABT-737 synergizes with
Bortezomib to kill melanoma cells. Biol Open 1:92–100
Reya T, Morrison SJ, Clarke MF et al. (2001) Stem cells, cancer, and cancer
stem cells. Nature 414:105–11
Robert C, Ribas A, Wolchok JD et al. (2014) Anti-programmed-death-receptor-1
treatment with pembrolizumab in ipilimumab-refractory advanced
melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Lancet 384:1109–17
Roberts AW, Seymour JF, Brown JR et al. (2012) Substantial susceptibility of
chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study
of navitoclax in patients with relapsed or refractory disease. J Clin Oncol
30:488–96
Roesch A, Fukunaga-Kalabis M, Schmidt EC et al. (2010) A temporarily distinct
subpopulation of slow-cycling melanoma cells is required for continuous
tumor growth. Cell 141:583–94
Schatton T, Murphy GF, Frank NY et al. (2008) Identiﬁcation of cells initiating
human melanomas. Nature 451:345–9
Shackleton M, Quintana E, Fearon ER et al. (2009) Heterogeneity in cancer:
cancer stem cells versus clonal evolution. Cell 138:822–9
Shakhova O, Sommer L (2013) Testing the cancer stem cell hypothesis in
melanoma: the clinics will tell. Cancer Lett 338:74–81
Shao Y, Aplin AE (2010) Akt3-mediated resistance to apoptosis in B-RAF-
targeted melanoma cells. Cancer Res 70:6670–81
Shao Y, Aplin AE (2012) BH3-only protein silencing contributes to acquired
resistance to PLX4720 in human melanoma. Cell Death Differ 19:2029–39
Snyder A, Makarov V, Merghoub T et al. (2014) Genetic basis for clinical
response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–99
Steelman LS, Chappell WH, Abrams SL et al. (2011) Roles of the Raf/MEK/ERK
and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging 3:192
Sun JG, Li H, Li X et al. (2014) Clitocine targets Mcl-1 to induce drug-resistant
human cancer cell apoptosis in vitro and tumor growth inhibition in vivo.
Apoptosis 19:871–82
Tabarestani S, Ghafouri-Fard S (2012) Cancer stem cells and response to
therapy. Asian Paciﬁc J Cancer Prev 13:5951–8
Thomas LW, Lam C, Edwards SW (2010) Mcl-1; the molecular regulation of
protein function. FEBS Lett 584:2981–9
Thomas S, Quinn BA, Das SK et al. (2013) Targeting the Bcl-2 family for cancer
therapy. Expert Opin Ther Targets 17:61–75
Tronnier M, Mitteldorf C (2014) Treating advanced melanoma: current insights
and opportunities. Cancer Manag Res 6:349–56
Tse C, Shoemaker AR, Adickes J et al. (2008) ABT-263: a potent and orally
bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421–8
van Delft MF, Wei AH, Mason KD et al. (2006) The BH3 mimetic ABT-737
targets selective Bcl-2 proteins and efﬁciently induces apoptosis via
Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389–99
Watson JT, Foo T, Wu J et al. (2013) CD271 as a marker for mesenchymal stem
cells in bone marrow versus umbilical cord blood. Cells Tissues Organs
197:496–504
Wei G, Margolin AA, Haery L et al. (2012) Chemical genomics identiﬁes small-
molecule MCL1 repressors and BCL-xL as a predictor of MCL1
dependency. Cancer Cell 21:547–62
Wilson WH, O'Connor OA, Czuczman MS et al. (2010) Navitoclax, a targeted
high-afﬁnity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-
escalation study of safety, pharmacokinetics, pharmacodynamics, and
antitumour activity. Lancet Oncol 11:1149–59
Wroblewski D, Mijatov B, Mohana-Kumaran N et al. (2013) The BH3-mimetic
ABT-737 sensitizes human melanoma cells to apoptosis induced by
selective BRAF inhibitors but does not reverse acquired resistance.
Carcinogenesis 34:237–47
Zeuner A, Francescangeli F, Contavalli P et al. (2014) Elimination of quiescent/
slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell
lung cancer. Cell Death Differ 21:1877–88
Zhang X, Tang N, Hadden TJ et al. (2011) Akt, FoxO and regulation of
apoptosis. Biochimica et Biophysica Acta 1813:1978–86
N Mukherjee et al.
Targeting BCL-2 Family Members to De-Bulk and Kill CSCs
www.jidonline.org 2161
